9 Meters Biopharma Q2 FY21: net loss $8.3M; diluted EPS −$0.60

Key figures from this report

These are the numbers 9 Meters Biopharma reported for Q2 FY21, the quarter ended Jun 30, 2021, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$8.3MAgainst −$44.6M in Q2 FY2010-Q income statement, on EDGAR
2. Diluted EPS−$0.60Against −$11.40 in Q2 FY20. Split-adjusted, as the tables show it; the filing reported −$0.0310-Q income statement, on EDGAR
3. Cash and cash equivalents$64.0M+375% from $13.5M in Q2 FY2010-Q balance sheet, on EDGAR
4. Cash from operations−$7.1MAgainst −$6.2M in Q2 FY2010-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters